Tibet Rhodiola Pharmaceutical Holding (600211.SH): The new production line for Xin Huosu is expected to commence formal production in the second half of the year after registration approval.

Gelonghui Finance · Jul 9 20:42

According to the investor relations activity records disclosed by Tibet Rhodiola Pharmaceutical Holding (600211.SH) on July 10th, the new production line of Xinhuosu is expected to be put into formal production after registering and approving in the second half of the year, and the total production capacity will reach 15 million units per year. The total investment of the production line is about 0.14 billion yuan. The company is expected to complete the transfer and consolidation next year according to the accounting standards and actual situations, and then depreciate or amortize it for 12 years, which will not have a significant impact on the company's profits.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

西藏药业(600211.SH)：新活素新产线预计下半年通过注册审批后投入正式生产

Tibet Rhodiola Pharmaceutical Holding (600211.SH): The new production line for Xin Huosu is expected to commence formal production in the second half of the year after registration approval.

Risk Disclaimer

Statement